文献速递免疫规划卫生政策与健康促进

超说明书疫苗使用的治理:全球国家免疫技术咨询小组网络的环境扫描

Governing off-label vaccine use: An environmental scan of the Global National Immunization Technical Advisory Group Network.
PubMed 文献 · Vaccine · 2019-11-27

对38个高、中、低收入国家的全球国家免疫技术咨询小组网络成员、免疫规划管理者和监管者进行环境扫描,通过在线调查和定性访谈了解超说明书疫苗推荐的理由、政策与程序。26/38(68%)国家有应答,14/26(54%)国家存在超说明书疫苗使用推荐,其中8/14(57%)由国家免疫技术咨询小组做出。障碍包括法律顾虑、缺乏超说明书使用的标准定义及制造商不愿更新产品信息。结论认为需要制定最佳实践指南。

要点

  • 14/26(54%)应答国家存在超说明书疫苗使用推荐,其中8/14(57%)由国家免疫技术咨询小组做出。
  • 超说明书推荐理由包括应对疾病暴发或疫苗短缺。
  • 仅1个国家有制定超说明书推荐的标准操作程序,6/14(43%)国家有实施政策。

核心结论

  • 需要制定最佳实践指南,界定超说明书使用并概述透明、基于证据的超说明书推荐制定方法。

研究设计与样本

  • 对38个高、中、低收入国家的全球国家免疫技术咨询网络成员、免疫规划管理者和监管者进行环境扫描。
  • 参与者完成关于超说明书推荐制定相关政策、程序和立法的在线调查。
  • 部分应答者参加焦点小组和个人访谈并进行定性分析。

主要发现

  • 26/38(68%)国家有34人应答,76%的应答者为国家免疫技术咨询小组成员或免疫规划管理者。
  • 14/26(54%)国家做出超说明书疫苗使用推荐,其中8/14(57%)国家由国家免疫技术咨询小组做出。
  • 超说明书疫苗推荐的理由包括应对疾病暴发或疫苗短缺。
  • 仅1个国家有制定超说明书推荐的标准操作程序,6/14(43%)国家有实施超说明书推荐的政策。
  • 来自8个国家的9名应答者同意参加焦点小组(n=6)或个人访谈(n=3)。

关键数值与推荐

  • 超说明书推荐的障碍包括法律顾虑、缺乏超说明书使用的标准定义以及制造商不愿更新产品信息。
  • 促进因素包括对决策过程的信心以及利益相关者之间公开沟通的透明度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: National Regulatory Authorities approve the indications for vaccine use in the product information. Occasionally, National Immunization Technical Advisory Groups (NITAGs) make off-label recommendations for use in different age groups, populations, and dosing schedules from the product information. We sought to determine the rationale, policies and procedures for NITAG off-label recommendations. METHODS: We conducted an environmental scan of Global NITAG Network members, immunization program managers and regulators in 38 high-, middle- and low-income countries. Participants completed an online survey regarding policies, procedures, and legislation governing development of off-label recommendations. A sub-sample of respondents met for a focus group and interviews which were analyzed qualitatively. RESULTS: Thirty-four people responded from 26/38 (68%) countries surveyed; 76% of respondents were NITAG members or immunization program managers. Recommendations for off-label vaccine use were made in 14/26 (54%) countries; the NITAG made those recommendations in 8/14 (57%) countries. Reasons for off-label vaccine recommendations included response to disease outbreaks or vaccine shortages. Only one country had standard operating procedures for developing off-label recommendations while 6/14 (43%) countries had policies for implementing off-label recommendations. Nine respondents from 8 countries agreed to participate in a focus group (n = 6) or individual interviews (n = 3). Barriers to off-label recommendations included legal concerns, lack of standard definition for off-label use, and manufacturer reluctance to update product information. Facilitators included confidence in the decision-making process, and transparency of open communication among stakeholders. CONCLUSIONS: Best practice guidelines are needed that define off-label use and outline a transparent, evidence-based approach to develop off-label recommendations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Top KA, Esteghamati A, Kervin M, et al. Governing off-label vaccine use: An environmental scan of the Global National Immunization Technical Advisory Group Network. Vaccine. 2019. PMID: 31786003. doi:10.1016/j.vaccine.2019.11.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。